All doses of experimental Ebola drug sent to WAfrica

A US company that makes an experimental drug for treating the often deadly Ebola virus said Monday it has sent all its available supplies to West Africa.

Some 961 people have died from the in Sierra Leone, Liberia, Guinea and Nigeria since March during the largest Ebola outbreak in history.

"In responding to the request received this weekend from a West African nation, the available supply of ZMapp is exhausted," said a statement on the Mapp Bio website.

"Any decision to use ZMapp must be made by the patients' medical team," it said, adding that the drug was "provided at no cost in all cases."

The biomedical collaboration between US and Canadian researchers involves a drug that is manufactured in tobacco leaves and is hard to produce on a large scale.

The company did not reveal which nation received the doses, or how many were sent.

CNN reported that Liberia was to receive the sample doses.

The two American missionary workers who fell ill with Ebola while working in Monrovia last month were given doses of the drug.

Both have been transported to an isolation unit at Emory University Hospital in Atlanta, Georgia, where they are receiving continuous care.

A Spanish priest who was sickened with Ebola has also been given a dose.

The ethics of distributing experimental medications to some people but not others was the focus of a special meeting of the World Health Organization on Monday.

The US Centers for Disease Control and Prevention has repeatedly stressed that the drug's effects are unknown, since it has not been through a process of rigorous clinical trials.

There is no medicine or vaccine for Ebola on the world market.

add to favorites email to friend print save as pdf

Related Stories

Spanish Ebola patient gets experimental drug

Aug 11, 2014

Spain has imported a U.S.-made experimental Ebola drug to treat a Spanish missionary priest evacuated from Liberia last week after testing positive for the killer virus.

Recommended for you

Powdered measles vaccine found safe in early clinical trials

11 hours ago

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.